AbbVie Stock Price, News & Analysis (NYSE:ABBV)

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie announced a -- dividend on Monday, September 9th. Shareholders of record on Tuesday, October 15th will be given a dividend of $1.07 per share on Friday, November 15th. This represents a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, October 11th. View AbbVie's Dividend History.

AbbVie announced that its Board of Directors has approved a stock repurchase program on Thursday, December 13th 2018, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 3.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's board believes its shares are undervalued.

AbbVie Inc (NYSE:ABBV) posted its quarterly earnings results on Friday, July, 26th. The company reported $2.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.05. The firm had revenue of $8.26 billion for the quarter, compared to analyst estimates of $8.09 billion. AbbVie had a negative return on equity of 182.70% and a net margin of 12.62%. The firm's quarterly revenue was down .3% on a year-over-year basis. During the same period last year, the business posted $2.00 EPS. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for AbbVie.

AbbVie will be holding an earnings conference call on Friday, November 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AbbVie updated its FY19 earnings guidance on Friday, July, 26th. The company provided earnings per share guidance of $8.82-8.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.78.

15 Wall Street analysts have issued 12-month price targets for AbbVie's shares. Their predictions range from $66.61 to $135.00. On average, they anticipate AbbVie's stock price to reach $89.20 in the next year. This suggests a possible upside of 21.1% from the stock's current price. View Analyst Price Targets for AbbVie.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Media headlines about ABBV stock have been trending negative recently, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for AbbVie.

AbbVie saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 51,014,000 shares, an increase of 11.2% from the July 31st total of 45,895,500 shares. Based on an average trading volume of 10,600,000 shares, the days-to-cover ratio is presently 4.8 days. Approximately 3.5% of the shares of the company are short sold. View AbbVie's Current Options Chain.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and Toronto-Dominion Bank (TD).

AbbVie's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Artemis Investment Management LLP (0.06%), Welch & Forbes LLC (0.03%), Manning & Napier Group LLC (0.03%), TIAA FSB (0.03%), Berkshire Asset Management LLC PA (0.02%) and Gulf International Bank UK Ltd (0.02%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Park National Corp OH, Decatur Capital Management Inc., Berkshire Asset Management LLC PA, Cypress Capital Group, Welch & Forbes LLC, Legacy Private Trust Co. and Crossmark Global Holdings Inc.. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

ABBV stock was acquired by a variety of institutional investors in the last quarter, including TIAA FSB, Thomasville National Bank, State of Alaska Department of Revenue, Bennicas & Associates Inc., North Star Investment Management Corp., Pacer Advisors Inc., HBW Advisory Services LLC and Gofen & Glossberg LLC IL. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $73.63.

AbbVie has a market capitalization of $108.86 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.